Department of Gastroenterology, the Second Xiangya Hospital, Central South University, Changsha, China.
Research Center of Digestive Disease, Central South University, Changsha, China.
Biomarkers. 2023 Dec;28(5):427-436. doi: 10.1080/1354750X.2023.2201664. Epub 2023 May 30.
Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC. PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages. A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients. Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction. This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.
循环肿瘤 DNA（ctDNA）在多种消化系统癌症中表现出强大的诊断准确性。然而，ctDNA 在胃癌（GC）中的预后作用仍存在争议。本系统评价和荟萃分析旨在评估 ctDNA 在 GC 中的预后价值。通过检索 PubMed、Web of Science 和 Cochrane 数据库，以识别使用 ctDNA 预测 GC 结果的研究，并纳入所有截至 2022 年 11 月发表的相关研究进行分析。两位作者独立提取数据，并使用 R 程序中的“meta”和“metafor”包进行统计分析。共有 34 篇符合条件的文章，涉及 5091 名患者，纳入我们的荟萃分析。GC 患者的总生存（OS）、无病生存（DFS）和无进展生存（PFS）的相应风险比（HR）分别为 2.74（95%CI：2.24-3.35）、3.13（95%CI：2.08-4.72）和 3.04（95%CI：2.46-3.76）。血液 ctDNA 检测可能是 GC 评估和预测的潜在新型生物标志物。这是一项关于循环肿瘤 DNA（ctDNA）与胃癌（GC）预后相关性的综合荟萃分析，随着近年来越来越多的研究探索 GC 的预后价值，该分析表明 ctDNA 的检测可能是 GC 患者有前途的预测指标。
